This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Dr. Michiko Kimoto, PhD
Chief Operating Officer, R&D Director at Xenolis Pte. Ltd.
Speaker

Profile

Michiko Kimoto earned her Ph.D. from the University of Tokyo before joining Dr. Ichiro Hirao’s lab at RIKEN in 2002, where she focused on expanding DNA’s genetic alphabet and developing methods for generating high-affinity DNA aptamers. In 2015, she moved to Singapore alongside Dr. Hirao to further research at A*STAR. In 2022, together with Dr. Hirao, she co-founded Xenolis Pte. Ltd., a company dedicated to the development of high-affinity XenoAptamers.

Agenda Sessions

  • Design and Selection of High-Affinity XenoAptamers for Diagnostic and Therapeutic Applications

    1:45pm